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OBJECTIVES: Analyze drug use and related costs of a RA patient cohort in UNIMED
Rio de Janeiro affiliate (HMO).METHODS:All RA patient information of age, weight,
height, sex, body mass index (BMI) data and biologic DMARDs use were collected
from March/2009 to March/2011. Drugs ex-factory prices were used to estimate
treatment costs. RESULTS: Sixty-nine patients were treated in the period of anal-
ysis. The cohort profile was: 86.9% woman and 13.1% man, mean age 51 years,
mean weight 65.85kg, mean height 1.60m and mean BMI 24.31; 71.21% of patients
have been diagnosed for more than 5 years, 16.67% from 2 to 5 years and 12.12%, 6
months to 2 years. Mean non-biological DMARD use was 2.27 years. From March/
2009 to March/2010, 5 patients were treated with infliximab, 2 with etanercept, 5
with adalimumab, 5 with abatacept, 3 with tocilizumab and 4 with rituximab.
Estimated drugs costs were BRL398,943.56, BRL145,266.68, BRL385,933.60,
BRL325,719.00, BRL154,190.40 and BRL124,228.32 respectively, resulting in a total of
BRL1,534,281.56 (mean BRL63,928.40/patient). From April/2010 to March/2011, 14
patients were treated with infliximab, 1 with etanercept, 5 with adalimumab, 8
with abatacept, 5 with tocilizumab and 12 with rituximab. Drugs acquisition costs
were BRL1,117,041.98, BRL72,633.34, BRL385,933.60, BRL521,150.40, BRL256,984.00
and BRL372,684.96 respectively, resulting in a total of BRL2,726,428.28
(BRL60,587.30/patient). CONCLUSIONS: Considering first-line biologic DMARDs, to-
cilizumab therapy was estimated to be the less expensive. Mean costs per patient
decreased in 5.23% from first to second period of analysis mainly because of growth
in rituximab treatment usage (from 16.7% to 26.7%).
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OBJECTIVES: To examine the association between teriparatide adherence and
health care utilization and costs in “real world” U.S. kyphoplasty/vertebroplasty
(KV) patients. METHODS: A large U.S. administrative claims database was used to
identify patients aged 50 with a KV between January 1, 2002-December 31, 2010
(first observed KVindex). All patients included had 6 months of pre-index con-
tinuous enrollment, and no pre-index teriparatide, cancer, or Paget’s disease. Pa-
tients initiating teriparatide were followed for up-to 36 months post-index (fol-
low-up period), with censoring at switch to bisphosphonates, disenrollment, end of
study period, or having cancer or Paget’s disease. Three teriparatide adherence
(measured as the proportion of days covered [PDC] over the follow-up period) co-
horts were constructed: low (PDC0.5), medium (0.5PDC0.8), and high
(PDC0.8). Repeated KV and per-patient per-month (PPPM) number of inpatient
admissions and costs (total, inpatient, outpatient, and pharmacy) were compared
between cohorts. Multivariable generalized linear models were used to examine
the association between teriparatide adherence and health care utilization and
costs, adjusting for patient characteristics. RESULTS: The study sample included
1568 patients (mean age: 75 years; 82% female), with 403 (26%), 382 (24%), and 783
(50%) in the low, medium, and high adherence groups, respectively. Adjusting for
differences in patient characteristics, high adherence was significantly (P0.05)
associated with the lowest PPPM inpatient (low$1,287; medium$1,005;
high$678) and outpatient (low$1,464; medium$1,244; high$1,077) medical
costs but increased pharmacy costs (low$752; medium$1,159; high$1,616) (all
P0.05), leading to similar total costs (low$3,344; medium$3,376; high$3,351)
between cohorts. The high adherence cohort also had the lowest (P0.05) odds of
repeated KV (odds ratio vs. high1.72 [low] and 1.73 [medium]) and number of
inpatient admissions (incidence rate ratio with base categoryhigh: low 1.61;
medium1.19). CONCLUSIONS: Among KV patients newly-initiating teriparatide,
significantly increased pharmacy costs associated with greater teriparatide adher-
ence were offset by significantly lower odds of repeated KV and significantly lower
medical resource use and costs.
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OBJECTIVES: Low persistence and poor compliance with prescribed medication are
important factors in treatment failure. This study estimated persistence and com-
pliance of post-menopausal (PMO) women in Hungary. METHODS: This retrospec-
tive analysis used patients’ data from the National Health Insurance Fund Admin-
istration (NHIFA). Subjects were females, 50 years old with a diagnosis of
osteoporosis (with ICD-10 codes, M80 or 81), who started an osteoporosis drug
prescription between Jan 2004 and Dec 2010. Treatment persistence was estimated
per active substance and administration types for 12 and 24 months with a 4-week
grace period. Compliance was measured by Medication Possession Ratio (MPR) and
a patient was considered compliant with treatment at one year if MPR80%.
RESULTS: A total of 223,068 patients matched inclusion criteria, of whom 49.6%
were older than 70 years, 6.4% had prior fractures at first index date, 79.5% were on
oral bisphosphonates (OBPs), 8.2% on intravenous (IV) BPs and 12.3% on other
therapies. Persistence analysis with a 4-week grace period showed 27.0% and 68.7%
of patients persistent after 1 year for oral and parenteral drugs respectively. Sen-
sitivity analyses with grace period of 8 weeks (43.7% and 75.8%) and 12 weeks
(60.8% and 79.5%) increased persistence rates. The lowest persistence after 12
months was observed in daily (20.5%) and monthly (20.0%) compared to quarterly
(48.8%) drugs, declining at 24 months to 7.6%, 4.9%, 28.5% and 34.9% for daily,
monthly, quarterly and yearly drugs, respectively. Only 33.2% of all patients were
compliant with treatment (i.e. MPR80%). Compliance was higher to parenteral
drugs (73.5%) than oral drugs (29.5%). The lowest compliance was observed with
daily oral drugs (only 18.9%); weekly and monthly drugs had similar compliance of
31%. CONCLUSIONS: Persistence and compliance are very low in osteoporosis
treatment of PMO women in Hungary. However, parenteral, less frequently admin-
istered drugs have higher persistence and better compliance.
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OBJECTIVES: To estimate persistence and compliance with prescribed osteoporo-
sis medication in male patients in Hungary.METHODS: This retrospective analysis
used patient data from the National Health Insurance Fund Administration
(NHIFA). Subjects were males 50 years old with a diagnosis of osteoporosis
(ICD-10 code M80 or 81) who filled an initial osteoporosis drug prescription between
Jan 2004 and Dec 2010. Treatment persistence was estimated per active substance
and administration types for 12 and 24 months with a 4-week grace period. Com-
pliance was measured by Medication Possession Ratio (MPR) and a patient was
considered compliant with treatment at 1 year if MPR80%. RESULTS: Of 19,905
patients, who matched inclusion criteria, 47.7% were older than 70 years and 6.4%
had prior fractures at first index date; 99.0% were on oral bisphosphonates (OBPs),
0.9% on intravenous (IV) BPs and 0.1% on other therapies. Persistence analysis with
a 4-week grace period showed 26.1% of patients were persistent after 1 year for oral
drugs declining after 2 years to 10.5%. For parenteral drugs, 16.4% of patients were
persistent after 2 years. Sensitivity analyses with grace periods of 8 weeks (21.7%
for oral and 19.1% for parenteral drugs) and 12 weeks (34.7% for oral and 55.0% for
parenteral drugs) increased persistence rates at 2 years. The lowest persistence
after 12 months was observed in weekly (26.1%) & monthly (37.6%) drugs, reaching
after 24 months 10.5%, 37.6% & 16.4% for weekly, monthly and yearly drugs, re-
spectively. Only 27.8% of all patients were compliant with treatment (i.e.
MPR80%). Compliance was higher to parenteral drugs (100%) than oral drugs
(27.5%). CONCLUSIONS: Persistence and compliance with oral osteoporosis
treatments are very low in male patients in Hungary. However, parenteral,
less-frequently administered drugs are associated with higher persistence and
better compliance.
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OBJECTIVES: Compliance to osteoporosis drugs is frequently very low leading to
increased fracture risk in patients. This study examined the factors associated with
fracture risk of post-menopausal osteoporotic (PMO) patients in Hungary with key
interest in compliance. METHODS: This retrospective analysis used patients’ data
from the National Health Insurance Fund Administration (NHIFA). Subjects were
females, 50 years old with a diagnosis of osteoporosis (ICD-10 codes, M80 or 81),
who started an osteoporosis drug prescription between Jan 2004 and Dec 2010. The
relationship between all factors and fracture risk was assessed using a dynamic
Cox regression model and the Andersen-Gill analysis estimating 95% confidence
intervals. RESULTS:A total of 223,068 patients were analysed and 128,610 matched
inclusion criteria for the fracture risk analysis with 46.9% older than 70 years; 6.4%
had prior fractures at index date (i.e. the start of the analysis period). Analysis
showed that compliant patients have an 18% (RR0.82, CI0.75-0.89) fracture risk
reduction versus non-compliant patients. Moreover, patients older than 70 years
had an increase in fracture risk of 26% (RR1.26, CI1.15-1.38) compared to pa-
tients aged 50-60 years old. Prior fractures were associated with a two-fold in-
creased risk of a new fracture (RR2.01, CI1.76-2.30) and almost with a three-fold
increased fracture risk (RR2.91, CI2.37-3.58) in patients with one and 2 prior
fractures respectively compared to patients with no prior fractures. Moreover, a
relationship was found between any co-medication and fracture risk with a 9%
(RR1.09, CI1.00-1.20) increase with one co-medication and a 32% (RR1.32,
CI1.19-1.47) with 2 co-medications compared to none. CONCLUSIONS:Age, any
co-medication and prior fractures were associated with an increased relative risk
of fracture. Compliance, however, was associated with protection against fracture
(reduction of relative fracture risk).
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OBJECTIVES: The use of historical or prospective cohorts of patients retrieved from
automated databases can provide different persistence estimates from self-re-
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ported data. The objective of this study was to estimate persistence to oral bispho-
sphonates (OBPs) in the Portuguese postmenopausal osteoporosis (PMO) popula-
tion, exploring different methods. METHODS: This was an observational,
prospective cohort study of women 50 years old with PMO who had not been
prescribed PMO treatment within 6 months prior to recruitment from community
pharmacies. Patients were classified as persistent if they refilled their prescription
within a 30-day grace period after exhausting the time covered by their previous
supply. For subgroup analysis, non-persistent patients were followed up by tele-
phone. Sensitivity analysis included 6 different methods, in particular, increasing
the grace period to 90 days and allowing a switch to other PMO medication.
RESULTS: A total of 427 women (mean age 65 years) were included in the analysis.
Persistence rates at 6 months of follow-up (interim analysis) varied from 27.6%
(95%CI 23.4%-32.0%) to 52.6% (95%CI 47.3%-57.6%) using pharmacy records exclu-
sively and additional patient report of BP acquisition in a different pharmacy (re-
ported by 113 of 269 patients), respectively. Allowing a longer grace period (90 days)
and switch to other PMO medications resulted in rates of 49.9% (95%CI 33.8%-64.0%)
and 28.6% (95%CI 24.3%-33.0%), respectively. CONCLUSIONS: Results at 6 months
showed a variation in persistence rate estimates depending on the method applied,
with increased estimates when self-reported data and longer grace periods were
used. Ongoing analysis will allow assessment of the impact of the different meth-
ods over longer follow-up periods.
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OBJECTIVES: To document the real-life use of golimumab in patients with Anky-
losing spondylitis (AS), Rheumatoid arthritis (RA) and Psoriatic arthritis (PsA), in
terms of treatment persistence/ discontinuation, adherence and switching
patterns. METHODS: This study was a single country (the Netherlands), retrospec-
tive database study of AS, RA and PsA patients treated with golimumab from March
17, 2010 onwards with last data collection being performed on October 3rd 2011.
RESULTS: The sample consisted of 882 patients (163 with AS, 216 with PsA and 503
with RA; 33% being male patients) with a maximum follow-up period of 57 weeks.
Forty-eight percent (n422) were naïve patients, while 52% (n460) were switched
from a previous anti-TNF treatment; 37% were previously treated with etanercept
and 38% with adalimumab, with no significant difference between the three indi-
cation groups. Among the switched patients, the main reason for switching to
golimumab were the lack of efficacy of the previous treatment (30.9%), the more
convenient frequency of administration with golimumab (27.0%) and unspecified
side-effects (18.8%). Temporary treatment discontinuation of golimumab was ob-
served in only 1.25% of the patients (n11). For these patients, adherence ranged
between 31.82% and 93.72%. The median time-to-dropout or median persistence
was 195 days when calculated in the whole population (n882). Sex and type of
patient (“naïve” vs. “switcher”) were identified as predictors, with a hazard ratio of
0.693 associated to male patients (vs. female patients; p-value0.014) and of 0.596
associated to naïve patients (vs. switchers; p-value0.001). CONCLUSIONS: Con-
venient frequency of administration has an impact on treatment decision making.
Sex and type of patient (“naïve” vs. “switcher”) were identified as predictors of
switch, with male patients and naïve patients associated with a higher persistence
to golimumab.
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OBJECTIVES: Comorbidities can influence generic measurement of health by
multi-attributes or indirect utility. We investigated the impact of comorbidities to
assess indirect utility with the Medical Outcomes Study Short Form 6D (SF-6D)
measuring health-related quality of life in patients with osteoarthritis (OA).
METHODS: The 878 patients, aged 45-75 years with symptomatic knee or/and hip,
of the KHOALA (Knee and Hip OsteoArthritis Long term assessment) cohort were
included in the study. Comorbidities were assessed by the Functional Comorbidity
Index (FCI) and grouped in 9 categories. Limitation in activities and pain was mea-
sured by the Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC).Two separate linear regression models, using the number of comorbidi-
ties or the different categories of comorbidities of the FCI, were fitted to determine
predictors of utility score. RESULTS: For the 878 patients included, the mean (SD)
utility score was 0.66 (11; range 0.32–1.00) and mean number of comorbidities 2.05
(1.58). In the first multivariate model, , for each additional comorbidity (range 0–9) the
mean utility score decreased of 0.01 point (beta -0.010, p0.0001). In the second
model, including comorbidities by categories, only psychiatric disease (beta-
0.043, p0.0001) and degenerative disc disease (beta-0.014, p0.018) predicted
low utility score. In both regression models a worsened function (increased
WOMAC function score) significantly decreased the utility score. The number of
comorbidities explained 2% of the variance in utility score (partial R-square0.02)
and psychiatric and degenerative disc diseases explained 2% (partial
R-square0.025) and 0.7% (partial R-square0.007), respectively, of the variance in
utility score, whereas the WOMAC function score explained 38% of the variance in
both models (partial R-square  0.38). CONCLUSIONS: Compared to greater nega-
tive effect of functional impairment, comorbidities have a negative but relatively
marginal impact on indirect utility score. This suggests that clinically, considering
the functional severity of OA remains a first priority.
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OBJECTIVES: In time trade-off (TTO) and standard gamble (SG) procedures for elic-
iting health state utilities, the duration of time spent in each health state is an
integral component of the task. The most common time horizon is 10 years, but
others are used, including personalized time horizons which aim to present real-
istic choices reflecting reasonable expectations of the respondent’s lifespan. The
purpose of this study was to examine implications of the time horizon used in
direct utility assessment.METHODS:UK general population participants rated four
health states (describing osteoarthritis) with a Visual Analog Scale (VAS), followed
by TTO and SG procedures with a 10-year time horizon. Half of the sample was
randomized to complete utility procedures again with a personalized time horizon
based on self-reported additional life expectancy. Scores were compared in terms
of discrimination between health states. RESULTS: The 10-year tasks were com-
pleted by 80 participants (mean age 47.3; 48.8% female), and 35 also completed
personalized time horizon procedures. Nearly all participants (97.5%) rated health
state A (mild osteoarthritis) higher than B (moderate) on the VAS. However, the
10-year tasks did not consistently detect this ranking, with only 32.5% (TTO) and
23.1% (SG) of respondents distinguishing between health states. The personalized
time horizon resulted in increased rates of discrimination between health states:
54.3% with both TTO and SG. This increase was statistically significant (TTO: chi-
square 4.9; p 0.03; SG: chi-square 10.7; p 0.001). Two other health state pairs
followed similar patterns, but without statistically significant differences between
time horizons. CONCLUSIONS: In this exploratory study, the personalized time
horizon resulted in better discrimination between health states than the fixed
10-year approach. When designing utility evaluations, researchers should carefully
consider the time horizon so that the relative value of health states are accurately
represented in cost-utility models.
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OBJECTIVES: To compare health utility estimated with the EQ-5D and the Time-
trade-off (TTO) instruments after vertebral fracture. METHODS: The International
Costs and Utilities Related to Osteoporotic fractures Study (ICUROS) is a prospec-
tive multinational study with the aim of estimating costs and health related quality
of life (HRQoL) related to osteoporotic fractures. In the study, two instruments were
used to estimate patients’ perceived health utility: the direct individual preference
based TTO instrument and the indirect EQ-5D instrument, valued by societal pref-
erences. Health utility was measured before fracture (recollection), and 2 weeks, 4
months and 12 months after fracture. RESULTS: In the 225 patients included in the
interim analysis, estimates of health utility elicited from the two instruments var-
ied significantly and the EQ-5D systematically provided lower estimates compared
to the direct TTO instrument. The smallest mean outcome difference was 0.10
(TTO: 0.91 and EQ-5D: 0.81), elicited before fracture and the largest difference was
0.20 (TTO: 0.44 and EQ-5D: 0.23), elicited after two weeks. The correlation coeffi-
cient for the health utility loss over 12 months, using Spearman’s correlation, for
the two instruments was 0.36 (p0.05). CONCLUSIONS: Osteoporotic vertebral
fractures give rise to significant loss of health utility, irrespective of instrument
used. However, there are substantial differences in the extent of the health utility
decrease assessed by the two instruments. The main explanation for these differ-
ences is that the instruments rely on different reference populations; respondents
of direct TTO act as their own reference and express preferences regarding their
own health state, whereas the EQ-5D reflects the preferences of healthy individuals
assessing hypothetical health states.
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OBJECTIVES: The selection of attributes represents an important step in the devel-
opment of discrete-choice experiments (DCE), but is often poorly reported. In some
situations, the number of identified attributes may exceed what one may find
possible to pilot in a DCE. Hence there is a need to gain insight into methods to
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